Infection with different HIV subtypes is associated with CD4 activation-associated dysfunction and apoptosis

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 5, 2009, Pages 548-552

  Bousheri, Stephanie ^a   Burke, Candace ^a   Ssewanyana, Isaac ^b   Harrigan, Richard ^c   Martin, Jeffrey ^d   Hunt, Peter ^d   Bangsberg, David R ^e   Cao, Huyen ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Partners AIDS Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOPTOSIS REGULATORY PROTEIN; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN;

ADULT; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UGANDA; CLASSIFICATION; FEMALE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; METABOLISM; PROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UGANDA;

EID: 73349093133     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181c1d456     Document Type: Article

References (17)

1. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008;197:707-713.
2. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infec Dis. 2002;185: 1244-1250.
3. Kaleebu P, Ross A, Morgan D, et al. Relationship between HIV-1 env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS. 2001;15:293-299.
4. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis. 2007;195:1177-1180.
5. Church JD, Huang W, Mwatha A, et al. HIV-1 tropism and survival in vertically infected Ugandan infants. J Infect Dis. 2008;197:1382-1388.
6. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr. 2007;45:28-33.
7. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol. 1999;17:625-656.
8. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infectionismainly due to immune activation: alongitudinal analysisinpatients before and during highly active antiretroviral therapy (HAART). Blood. 2000;95:249-255.
9. Eggena MP, Barugahare B, Okello M, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis. 2005;191:694-701.
10. Baker CA, Bousheri S, Ssewanyana I, et al. HIV subtypes distribution and implication for antiretroviral treatment in a Ugandan population. J Int Assoc Physicians AIDS Care (Chic Ill). 2007;6:260-263.
11. Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr. 2008;49: 266-271.
12. Rizzardini G, Piconi S, Ruzzante S, et al. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS. 1996;10:1535-1542.
13. Eggena MP, Barugahare B, Jones N, et al. Depletion of regulatory T Cells in HIV infection is associated with immune activation. J Immunol. 2005; 174:4407-4414.
14. Katzenstein TL. Molecular biological assessment methods and understanding the course of the HIV infection. APMIS Suppl. 2003;114: 1-37.
15. Hazenberg MD, Otto SA, Wit FW, et al. Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss. AIDS. 2002;16:1287-1289.
16. Sufka S, Ferrari G, Gryszowka V, et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infec Dis. 2003;187:1027-1037.
17. Baker CA, Emenyonu N, Ssewanyana I, et al. Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy. AIDS Res Hum Retroviruses. 2007;23:900-905.